Want to see EXOZ full AI Analyst Report?
Top Page
eXoZymes
(NASDAQ:EXOZ)
Select Model
Select Model
Rating:44Neutral
Price Target:
$7.50
▲(70.45% Upside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by very weak financial performance (no revenue, widening losses, and persistent cash burn), with technicals also unfavorable given the price remains below key longer-term moving averages and MACD is negative. Corporate events provide some offset via improved funding visibility (NIH grant and recent capital raises), but the financing structure introduces dilution risk, and valuation is difficult to support with a negative P/E driven by losses.
Positive Factors
NIH-backed cannabinoid pipeline
The NIH grant provides two years of non-dilutive support for rare cannabinoid production, analog development and preclinical testing. This expands the pipeline beyond NCT and may improve partnership potential if the platform produces viable pharmaceutical candidates.
Negative Factors
No commercial revenue
The absence of revenue indicates that the company has not yet demonstrated commercial product-market fit or recurring demand. Continued reliance on pipeline advancement and external funding makes future performance dependent on successful development and commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
NIH-backed cannabinoid pipeline
The NIH grant provides two years of non-dilutive support for rare cannabinoid production, analog development and preclinical testing. This expands the pipeline beyond NCT and may improve partnership potential if the platform produces viable pharmaceutical candidates.
Read all positive factors
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$64.51M
Dividend YieldN/A
Average Volume (3M)2.40K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth-21.64%
CountryUS
Employees32
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.20
Shares Outstanding9,281,359
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, ...
How the Company Makes Money
null...
eXoZymes Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.61K | 0.00 | -267.38K | 0.00 | -147.75K | -59.41K |
| EBITDA | -10.58M | -8.98M | -5.59M | -1.80M | -1.18M | -1.15M |
| Net Income | -10.19M | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | ||||||
| Total Assets | 7.98M | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.65M | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.09M | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 4.33M | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 3.65M | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | ||||||
| Free Cash Flow | -7.14M | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -7.00M | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -145.90K | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | 5.81M | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Risk Analysis
eXoZymes disclosed 47 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
eXoZymes Peers Comparison
UnderperformOutperform
Sector (55)
EXOZ
eXoZymes
7.53
-2.07
-21.56%
BDRX
Biodexa Pharmaceuticals
1.18
-26.72
-95.77%
ADTX
Aditxt
0.04
-25,872.44
-100.00%
NCEL
NewcelX
3.48
-17.92
-83.74%
VRAX
Virax Biolabs Group Ltd. Class A
2.91
-12.92
-81.62%
eXoZymes Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
eXoZymes Completes New Securities Offering to Fund Pipeline
Positive
Jul 1, 2026
On June 30, 2026, eXoZymes Inc. closed a registered securities offering of 35,555 units, each comprising one common share and one warrant, at $18.00 per unit, raising gross proceeds of about $640,000 and net proceeds after fees and expenses of rou...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Secures NIH Grant to Advance Cannabinoid Pipeline
Positive
Jun 26, 2026
On June 24, 2026, eXoZymes Inc. announced it had secured a $2.03 million Phase IIB Small Business Innovation Research grant from the National Institute of General Medical Sciences of the NIH to advance rare cannabinoid production and engineered ca...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Completes Nasdaq Equity Offering to Fund Pipeline
Positive
Jun 17, 2026
On June 17, 2026, Los Angeles-based eXoZymes Inc. announced the closing of an underwritten public offering of 330,575 units of common stock and warrants on Nasdaq, including 34,440 units issued through a partial exercise of the underwriters’...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Announces Public Equity Offering to Fund Growth
Positive
Jun 8, 2026
On June 5, 2026, eXoZymes Inc. entered into an underwriting agreement with MDB Capital for a firm commitment public offering of 592,270 common shares and 292,135 warrants, sold as units of two shares and one warrant at $18.00 per unit. The transac...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.